114583-24-3

Upstream product

• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 10387-40-3 potassium thioacetate 
• 127-08-2 potassium acetate 

Downstream Products

• 192775-41-0 2-(4-nitro-phenyl)ethanesulfonic acid 

Relevant academic research and scientific papers

Golden Opportunity: A Clickable Azide-Functionalized [Au25(SR)18]- Nanocluster Platform for Interfacial Surface Modifications

Ultrasmall atomically precise monolayer-protected gold thiolate nanoclusters are an intensely researched nanomaterial framework, but there is a lack of a system that can be directly synthesized and undergo interfacial surface chemistry. We report an [Au25(SCH2CH2-p-C6H4-N3)18]- nanocluster platform with azide moieties appended onto each surface ligand. The structure of this surface reactive cluster has been confirmed by single-crystal X-ray crystallography, mass spectrometry and ultraviolet visible, infrared and nuclear magnetic resonance spectroscopies. We show that all surface azide moieties are amenable to cluster-surface strain-promoted alkyne-azide cycloaddition chemistry with a strained cyclooctyne, opening this as a new platform to allow functional, postassembly surface modifications to this very prominent nanocluster.

Pyrido[2,3-d]pyrimidin-5-ones: A novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors

A series of pyrido[2,3-d]pyrimidin-5-ones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). FMS inhibitors may be useful in treating rheumatoid arthritis and other chronic infla

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.

Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres

Starting from phenethanolamine aniline leads 3a and 3b, we have identified a series of functionally potent and selective β3 adrenergic receptor (AR) agonists containing acylsulfonamide, sulfonylsulfonamide, or sulfonylurea groups within the ani